New Ideas, Funding Infused into Search for Blood Markers of Cancer

February 23, 2007

Clinicians dream of being able to diagnose cancer reliably with a simple lab test. Cancerous cells make some proteins abnormally. Some of these proteins are secreted or shed, and make their way into body fluids. The quest to identify proteins in blood or urine that ...

Antibody Signal May Redirect Inflammation to Fuel Cancer

February 19, 2007

As evidence mounts that the body's normally protective inflammation response can drive some precancerous tissues to become fully malignant, UCSF scientists report discovering an apparent trigger to this potentially deadly process. Typically, the "innate" immune system's Pac-Man-like white blood cells, or leukocytes, engulf and destroy ...

Personalized Vaccines to Fight Brain Cancer

February 7, 2007

UCSF neurosurgeon Andrew Parsa, MD, PhD, is running a clinical trial on patients with glioblastoma multiforme, the most deadly type of brain tumor, using a vaccine made from the patient's own tumor to trigger the immune system. In the clinical trial, Parsa first removes as ...

Insights into p53 Tumor-Suppressor Gene to Fuel Cancer Strategy

January 26, 2007

UCSF scientists are reporting key insights into the p53 tumor-suppressor gene that they say should help harness the gene to treat cancer. The gene is disabled in most forms of the disease, and its loss is often associated with increased malignancy, resistance to treatment and ...

Health Disparities Expert Named Chair of Department of Radiation Oncology

January 22, 2007

Mack Roach III, MD, professor of radiation oncology and urology, has been named chair of the Department of Radiation Oncology. "Dr. Roach is recognized as one of America's leading authorities on the use of radiation to treat localized prostate cancer and as a prominent crusader ...

Alternatives to Surgery and Radiation for Prostate Cancer

January 11, 2007

Due to aggressive prostate cancer screening, more men than ever before are being diagnosed with small, low-grade tumors that may pose little immediate threat. Oncologists are offering some of these men close monitoring -- called active surveillance -- without any immediate treatment. Why not treat?